DDX53 and neoplasm: Briefly, we combined a suboptimal dose of LPP-CT26 (10 μg) and a-PD1 in the subcutaneous CT26 tumor model (Fig. 8A) and found that the combination therapy markedly retarded tumor growth compared to a-PD1 or LPP-CT26 monotherapies (Fig. 8, B and E) leading to smaller end point tumor volume (Fig. 8C), higher tumor inhibition rate (Fig. 8D), and more prolonged animal survival (Fig. 8F).